DZNE Ulm
Ulm is the tenth, and youngest, site of the DZNE: Since 2018, scientists at the DZNE Ulm have been focusing in particular on rarer, but very serious nerve diseases, such as amyotrophic lateral sclerosis (ALS), types of frontotemporal lobar degeneration (FTLD), and Huntington’s disease. The goal of the site in Ulm is to translate the scientific results from fundamental research into clinical applications as quickly as possible: Plans call for developing new diagnostic and therapeutic procedures so that patients can benefit from them. New formats for clinical studies are being created as well. To this end, a clinical study center is currently being established at the DZNE Ulm, in close cooperation with the Department of Neurology at the Ulm University Hospital.
We’re researching ways to detect fatal neurological diseases like ALS, Parkinson's and FTD earlier and treat them more effectively.
The DZNE experts in Ulm are particularly interested in biomarkers, which are measurable biological indicators that can be used to detect a disease and assess how it will progress. To achieve this, the site is developing new technologies that can be used to detect biomarkers. Research in Ulm also focuses on therapeutic concepts that target pathogenic genetic defects.
Your commitment can make a big difference!
By participating in scientific studies, donating brain tissue or providing financial support, you can make a significant contribution to medical progress and a healthy future.
Clinical Trials Unit (CTU)
Further information and contact to our study team can be found here.
Clinical studies
Here you will find a current overview of our clinical studies.
Site coordination
Dr. Daniel Preiß
Contact
office-ulm(at)dzne.de
+49 731 177-1719
Address
Oberer Eselsberg 45
89081 Ulm
Printable directions
